XML 43 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
NOTE 10 - SHARE-BASED COMPENSATION
6 Months Ended
Jun. 30, 2012
Share-based Compensation [Abstract]  
NOTE 10 - SHARE-BASED COMPENSATION

For share-based awards granted, we have recognized compensation expense based on the estimated grant date fair value method.  For these awards we have recognized compensation expense using a straight-line amortization method and reduced for estimated forfeitures.  

  

 

The impact on our results of operations of recording share-based compensation for the three and six months ended June 30, 2012 and June 30, 2011, respectively, was as follows:

 

  Three Months Ended   Six Months Ended
  June 30,
2012
  June 30,
2011
  June 30,
2012
  June 30,
2011
(in thousands)              
Cost of goods sold $15   $12   $26   $21
Research and development 34   23   60   32
Selling, general and administrative 101   88   195   157
Total share-based compensation $150   $123   $281   $210
               
Impact on net income per share:              
Basic and diluted ($0.02)   ($0.01)   ($0.03)   ($0.02)

 

 

The fair value of share-based awards for employee stock options was estimated using the Black-Scholes valuation model.  The following weighted average assumptions were used to calculate the fair value of stock options granted during the three months and six months ended June 30, 2012 and 2011:

 

  Three Months Ended   Six Months Ended
  June 30,
2012
  June 30,
2011
  June 30,
2012
  June 30,
2011
               
Risk-free interest rates 0.61%   1.41%   0.62%   1.40%
Volatility factors 0.53   0.55   0.53   0.55
Expected life of the option in years 4.00   4.00   4.00   4.00
Expected dividend yield None   None   None   None

 

Option grants during the three and six months ended June 30, 2012 was 175,000 and 190,000 respectively.  Option grants during the  three and six months ended June 30, 2011 was 0 and 322,000 respectively.

 

At June 30, 2012, there remained approximately $1,182,586 of unamortized expected future compensation expense associated with unvested option grants and restricted stock awards, with a remaining weighted average amortization period of 2.59 years.